Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction

Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Viscuse, Paul V., Marques-Piubelli, Mario L., Heberton, Meghan M., Parra, Edwin Roger, Shah, Amishi Y., Siefker-Radtke, Arlene, Gao, Jianjun, Goswami, Sangeeta, Ivan, Doina, Curry, Jonathan L., Campbell, Matthew T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970171/
https://www.ncbi.nlm.nih.gov/pubmed/33747934
http://dx.doi.org/10.3389/fonc.2021.621591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970171/
https://www.ncbi.nlm.nih.gov/pubmed/33747934
http://dx.doi.org/10.3389/fonc.2021.621591

Ejemplares similares